GlassScriptPhysician profile
Clyde Columbus Mathison
NPI 1154505428
$65,777.77
in general payments reported to CMS, 2019-2025
27 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $2,143 · 2021: $10K · 2022: $29K · 2023: $254 · 2024: $806 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $63,050.29 | 2019-2025 | Clarifix, Xpress Loprofile |
| Intersect Ent, INC. | $540.72 | 2019-2022 | |
| Genzyme Corporation | $375.89 | 2022-2025 | |
| Glaxosmithkline, LLC. | $354.15 | 2022-2025 | Nucala |
| Inspire Medical Systems, INC. | $237.41 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $237.18 | 2021-2025 | Dupixent |
| Acclarent, INC | $228.82 | 2019-2021 | |
| Integra Lifesciences Corporation | $211.32 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Novartis Pharmaceuticals Corporation | $60.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $53.51 | 2019-2025 | Keytruda |
| Hikma Pharmaceuticals USA | $52.32 | 2024-2025 | Ryaltris |
| Alk-Abello, INC | $38.46 | 2021-2022 | |
| Optinose US, INC. | $38.42 | 2024 | |
| Davol INC. | $36.60 | 2020 | |
| Acera Surgical, INC. | $35.80 | 2024-2025 | Restrata Wound Matrix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biowound Solutions, INC. | $31.53 | 2025 | Bio-Connekt |
| Neurent Medical Limited | $28.73 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Organogenesis INC. | $28.27 | 2024 | |
| Baxter Healthcare | $24.65 | 2025 | Perclot |
| Aerin Medical INC. | $22.35 | 2019-2023 | |
| Covidien LP | $20.80 | 2019 | |
| Cook Medical LLC | $16.17 | 2021 | |
| Xoran Technologies LLC | $14.18 | 2020 | |
| Medtronic, INC. | $14.11 | 2025 | Slide-On Endosheath |
| Ambu INC. | $13.44 | 2020 | |
| Olympus America INC. | $11.73 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$142,375.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Mathison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.